Three times a day I take a drug called levodopa. I take it because my brain does not produce enough dopamine, without it my hands and feet shake and I have difficulty getting my body to do what I want it to do. These are symptoms of Parkinson's disease and mean that many of my dopamine producing neurons have died. But, thanks to levodopa, I can feed my brain synthetic dopamine. It is an incredible little drug that we discovered to be naturally produced in the broad bean plant, pictured here.
MIT researchers have devised a miniaturized system that can deliver tiny quantities of medicine to brain regions as small as 1 cubic millimeter. This type of targeted dosing could make it possible to treat diseases that affect very specific brain circuits, without interfering with the normal function of the rest of the brain, the researchers say.
AI has pervaded our homes, our cars, and now, our hospitals. They are built into our devices, and into our phones, and are the basis for 24 hour care – and increasingly used in drug discovery. Massive data sets are now used to monitor, detect, and address so many conditions, from heart disease to mental illness to the deterioration of gait in Parkinson's disease. Brain computer interfaces are allowing the disabled to walk, and the blind to navigate. Robots, and NLP tools such as Alexa, let seniors to age in place, gracefully. All of this makes healthcare accessible and more accurate.
"Recognition of the effects of this disease on me has been painful, and I have been slow to grasp the gravity of it," he wrote. "For me, a Parkinson's diagnosis is not a stop sign but rather a signal that I must make lifestyle changes and dedicate myself to physical therapy in hopes of slowing the disease's progression."
To commemorate the silver jubilee of FICO's use of artificial intelligence and machine learning, we asked FICO employees a question: What does the future of AI look like? The post below is one of the thought-provoking responses, from Shafi Rahman, a principal scientist at FICO, working in San Diego.
Intel CEO Brian Krzanich says the chip giant is deeply committed to unlocking the promise of AI. Intel has invested more than $1bn to date in artificial intelligence (AI) start-ups via its Intel Capital arm, according to company CEO Brian Krzanich. This includes investments in companies such as Mighty AI, DataRobot, Lumiata, AEye and others. 'AI will make the impossible possible: advancing research on cancer, Parkinson's disease and brain disorders; helping to find missing children; and furthering scientific efforts in climate change, space exploration and oceanic research' – BRIAN KRZANICH As well as investments, Intel has been pretty acquisitive in the AI start-up space, spending an estimated $16bn in recent years, the majority of which went into Israeli automotive tech player Mobileye, at $15.3bn. A year ago, Intel acquired Irish chip company Movidius for an undisclosed sum, as well as Nervana.